New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:47 EDTJNJ, CGJNJ accepts $4B binding offer from Carlyle to acquire Ortho-Clinical Diagnostics
Johnson & Johnson (JNJ) announced that it has accepted the binding offer from Carlyle Group (CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions. :theflyonthe
News For JNJ;CG From The Last 14 Days
Check below for free stories on JNJ;CG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2014
13:20 EDTJNJPharmacyclics granted regular approval for Imbruvica
Subscribe for More Information
12:52 EDTCGCarlyle in advanced discussions to acquire Acosta, Reuters says
Subscribe for More Information
12:26 EDTJNJPharmacyclics off lows, turns positive after FDA expands Imbruvica indication
Subscribe for More Information
12:24 EDTJNJFDA expands approved use of Imbruvica for chronic lymphocytic leukemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17, which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new labeling to reflect that Imbruvica’s clinical benefit in treating CLL has been verified. Imbruvica’s new use is being approved more than two months ahead of the product’s prescription drug user fee goal date of Oct. 7, the date the FDA was scheduled to complete review of the drug application. Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvica’s clinical benefit in mantle cell lymphoma are ongoing. Imbruvica is being jointly developed and commercialized in the United States by Pharmacyclics (PCYC) and Janssen Biotech (JNJ).
08:10 EDTCGOrtho-Clinical Diagnostics, Astute Medical to develope acute kidney injury tests
Subscribe for More Information
06:32 EDTJNJJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 25, 2014
08:54 EDTJNJEMA issues positive opinion, recommends approval of Imbruvica
Subscribe for More Information
07:17 EDTJNJEMA recommends approval for Gilead, Janssen blood cancer drugs
Subscribe for More Information
July 24, 2014
09:16 EDTJNJOn The Fly: Pre-market Movers
Subscribe for More Information
08:39 EDTJNJOrganovo enters 3D bio-printed tissue agreement with J&J unit
Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.
08:30 EDTCGCarlyle may be last firm in rigging suit as peers near settlement, NY Post says
Carlyle Group (CG) may soon be the only private equity firm left to settle a suit that accused it and several of its peers of conspiring to hold down deal prices and one source close to the situation said “my expectation is there will be a trial,” according to The New York Post. Bain Capital, Silver Lake and Goldman Sachs (GS) previously settled for a combined $150.5M and KKR (KKR), Blackstone (BX) and TPG Capital are expected to settle for an amount above that "within days," the report said. Reference Link
08:19 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2014
08:01 EDTCGBlackstone acquires majority stake in Service King Collision Repair Centers
Subscribe for More Information
July 22, 2014
19:34 EDTCGJPMorgan in advanced talks to sell half its stake in buyout arm, WSJ says
Subscribe for More Information
15:49 EDTCGBlackstone to buy majority stake in Service King from Carlyle, WSJ says
Blackstone's (BX) purchase from Carlyle Group (CG) of the majority stake in the repair chain values the company at about $650M, according to The Wall Street Journal, citing a source. Reference Link
14:25 EDTCGBlackstone to buy majority stake in Service King from Carlyle, Dow says
Subscribe for More Information
July 21, 2014
18:40 EDTJNJOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
17:03 EDTJNJJohnson & Johnson announces $5B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $5B of the company's common stock. The company had approximately 2.82B shares of common stock outstanding as of June 29.
17:01 EDTJNJJohnson & Johnson announces $5B share repurchase program
July 18, 2014
07:14 EDTCGBlackstone, KKR, TPG discussing deal collusion suit settlement, Reuters says
Blackstone (BX), KKR (KKR) and TPG Capital are in discussions to settle a U.S. case accusing the firms of conspiring not to outbid one another and other buyout companies on takeovers of firms, according to Reuters, citing two people familiar with the matter. If all three companies settled, the Carlyle Group (CG) would be the only private equity company still up against a trial among 11 firms originally accused of colluding in agreements before the financial crisis occurred. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use